OBJECTIVES: Interleukin (IL)-8 is one of several angiogenic factors produced in bladder cancer cell lines. Although many studies have indicated that IL-8 is increased in infectious/inflammatory processes, elevated levels of IL-8 in urine also may be indicative of active transitional cell carcinoma (TCC). METHODS: Urinary IL-8 levels were measured with an enzyme-linked immunosorbent assay in subjects with TCC (n = 51), prostate cancer (n = 17), or a history of successfully treated TCC (n = 23) and in healthy subjects (n = 49). In addition, urinary IL-8 levels were measured in 21 subjects before, during, and 1 month after intravesical therapy with bacille Calmette-Guérin or mitomycin C. RESULTS: The median urinary IL-8 levels were greater in subjects with TCC (64 pg/mL urine) than in healthy subjects (6 pg/mL urine), subjects with prostate cancer (0.5 pg/mL urine), or subjects with a history of successfully treated TCC (5.0 pg/mL urine). Urinary IL-8 levels were greater in subjects with invasive (high-stage) TCC than in those with low-stage TCC. Furthermore, the postintravesical instillation levels of urinary IL-8 levels were greater in patients whose TCC recurred compared with those whose TCC was in remission. CONCLUSIONS: IL-8 levels were greater in subjects with TCC compared with those with successfully treated TCC. IL-8 levels increased with TCC stage, indicating that they are greater in more invasive (ie, angiogenic) tumors. A reduction in urinary IL-8 levels after treatment with bacille Calmette-Guérin or mitomycin C may reflect a decrease in bladder cancer cells and/or in other cells that produce IL-8.
OBJECTIVES:Interleukin (IL)-8 is one of several angiogenic factors produced in bladder cancer cell lines. Although many studies have indicated that IL-8 is increased in infectious/inflammatory processes, elevated levels of IL-8 in urine also may be indicative of active transitional cell carcinoma (TCC). METHODS: Urinary IL-8 levels were measured with an enzyme-linked immunosorbent assay in subjects with TCC (n = 51), prostate cancer (n = 17), or a history of successfully treated TCC (n = 23) and in healthy subjects (n = 49). In addition, urinary IL-8 levels were measured in 21 subjects before, during, and 1 month after intravesical therapy with bacille Calmette-Guérin or mitomycin C. RESULTS: The median urinary IL-8 levels were greater in subjects with TCC (64 pg/mL urine) than in healthy subjects (6 pg/mL urine), subjects with prostate cancer (0.5 pg/mL urine), or subjects with a history of successfully treated TCC (5.0 pg/mL urine). Urinary IL-8 levels were greater in subjects with invasive (high-stage) TCC than in those with low-stage TCC. Furthermore, the postintravesical instillation levels of urinary IL-8 levels were greater in patients whose TCC recurred compared with those whose TCC was in remission. CONCLUSIONS:IL-8 levels were greater in subjects with TCC compared with those with successfully treated TCC. IL-8 levels increased with TCC stage, indicating that they are greater in more invasive (ie, angiogenic) tumors. A reduction in urinary IL-8 levels after treatment with bacille Calmette-Guérin or mitomycin C may reflect a decrease in bladder cancer cells and/or in other cells that produce IL-8.
Authors: Kai Qu; Jian Gu; Yuanqing Ye; Stephen B Williams; Colin P Dinney; Xifeng Wu; Ashish Kamat Journal: Oncoimmunology Date: 2017-01-03 Impact factor: 8.110
Authors: Li-Mei Chen; Myron Chang; Yunfeng Dai; Karl X Chai; Lars Dyrskjøt; Marta Sanchez-Carbayo; Tibor Szarvas; Ellen C Zwarthoff; Vinata Lokeshwar; Carmen Jeronimo; Alexander S Parker; Shanti Ross; Michael Borre; Torben F Orntoft; Tobias Jaeger; Willemien Beukers; Luis E Lopez; Rui Henrique; Paul R Young; Virginia Urquidi; Steve Goodison; Charles J Rosser Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-06-11 Impact factor: 4.254
Authors: Shailaja K Rao; Zoran Pavicevic; Ziyun Du; Jong-Gwan Kim; Meiyun Fan; Yan Jiao; Molly Rosebush; Sandeep Samant; Weikuan Gu; Lawrence M Pfeffer; Christopher A Nosrat Journal: J Biol Chem Date: 2010-08-11 Impact factor: 5.157
Authors: Virginia Urquidi; Myron Chang; Yunfeng Dai; Jeongsoon Kim; Edward D Wolfson; Steve Goodison; Charles J Rosser Journal: BMC Urol Date: 2012-05-04 Impact factor: 2.264
Authors: Cherith N Reid; Michael Stevenson; Funso Abogunrin; Mark W Ruddock; Frank Emmert-Streib; John V Lamont; Kate E Williamson Journal: PLoS One Date: 2012-12-31 Impact factor: 3.240